Zhiliang Xu | Medicine and Health Sciences | Best Researcher Award

Prof. Zhiliang Xu | Medicine and Health Sciences | Best Researcher Award

Wannan Medical College | China

Prof. Zhiliang Xu, affiliated with Wannan Medical College, Wuhu, China, is a distinguished molecular biologist and epigenetics researcher whose work focuses on histone ubiquitination, chromatin remodeling, and their implications in neurological disorders, cancer, gametogenesis, and cellular reprogramming. He earned his Ph.D. from the State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences in 2017. According to Scopus, Prof. Zhiliang Xu has authored 11 publications, which have been cited 34 times, and he holds an h-index of 4, demonstrating the impact of his research in the scientific community. His seminal studies elucidated the role of H2B ubiquitination in chromatin relaxation during meiosis and cellular reprogramming, published in journals such as Nucleic Acids Research (2016), Cell Proliferation (2021), and Reproduction (2017). His recent work on neuronal repair, gut-liver axis regulation in diabetes, and genomic approaches to thalassemia has been featured in FASEB Journal (2025), Annals of Hematology (2025), and Neuroscience Letters (2025). Prof. Zhiliang Xu leads multiple high-impact national and provincial research projects, serves as a peer reviewer for journals including Scientific Reports and Neurochemical Research, and evaluates theses for graduate and doctoral candidates. Recognized with the 2021 National Maternal and Child Health Science and Technology Award (First Prize), the 2022 Guangzhou High-level Talent Award, and the 2024 Outstanding Young Talent honor in Anhui Province, Prof. Zhiliang Xu continues to advance fundamental understanding of chromatin biology and epigenetic regulation, exemplifying excellence, mentorship, and translational scientific impact, making him an outstanding candidate for the Best Researcher Award.

Profile: Scopus | ORCID

Featured Publications

1. Shi, L., Yan, X., Xia, Y., Zhao, Y., Zhu, X., Li, Q., & Xu, Z. (2025). Beyond transfusions and transplants: Genomic innovations rewriting the narrative of thalassemia. Annals of Hematology.

2. Zhang, Y., Wang, J., Huang, S., Liu, M., Zhao, Y., Xu, Z., & Zhu, X. (2025). Electroacupuncture preconditioning alleviates cortical neuronal injury in cerebral ischemia-reperfusion by rebalancing HES1 and NF-κB expression. Neuroreport.

3. Yan, X., Shi, L., Zhu, X., Zhao, J., Zhao, Y., Luo, J., Li, Q., & Xu, Z. (2025). From microbial homeostasis to systemic pathogenesis: A narrative review on gut flora’s role in neuropsychiatric, metabolic, and cancer disorders. Journal of Inflammation Research.

4. Huang, S., Lu, Y., Fang, W., Huang, Y., Li, Q., & Xu, Z. (2025). Neurodegenerative diseases and neuroinflammation-induced apoptosis. Open Life Sciences.

5. Li, Q., Zhang, L., Sun, Y., Du, Z., Xu, S., Wang, X., Wei, S., Tao, Y., Li, B., Jiang, J., Di, G., Huang, Y., & Xu, Z. (2025). p53 modulates the gut-liver axis via PI3K/AKT/Wnt signaling pathways in type 2 diabetes. FASEB Journal.

6. Li, Q., Yan, X., Zhao, Y., Xu, Z., & Zhu, X. (2025). Paeonol mitigates chronic stress-induced amygdalar neuronal damage through glycogen synthase kinase-3β/calcineurin axis regulation of synaptic plasticity. Neuroreport.

7. Zhu, X., Zhang, Y., Yan, X., Zhao, Y., Shi, L., Sun, Z., Meng, K., Zong, Y., Li, Q., & Xu, Z. (2025). Paeonol facilitates the repair of neuronal damage in the mPFC caused by chronic stress via the Rho GTPases-cofilin1 signaling pathway. Neuroscience Letters, 138329.

Jing Zhuang | Oncology | Best Researcher Award

Ms. Jing Zhuang | Oncology | Best Researcher Award

Huzhou Central Hospital | China

Zhuang Jing is a dedicated head nurse at Huzhou Central Hospital with a master’s degree in nursing. She plays a pivotal role in the Zhejiang-France United Laboratory of Integrated Traditional Chinese and Modern Medicine in Colorectal Cancer and the Key Laboratory of Multiomics Research and Clinical Transformation of Digestive Cancer of Huzhou. Her research focuses on digestive tumors and intestinal microecology, contributing significantly to clinical advancements and patient care.

Professional profile👤

ORCID

Scopus

Strengths for the Awards✨

🎗️ Zhuang Jing has demonstrated a remarkable commitment to advancing research in colorectal cancer with a focus on intestinal microecology. As a leading member of the Zhejiang-France United Laboratory and the Key Laboratory of Multiomics Research and Clinical Transformation of Digestive Cancer, her involvement in 36 research projects and authorship of over 50 SCI-indexed publications reflect her substantial contribution to the field. Additionally, her work’s impact is evidenced by an H-index of 13 and two patents, showcasing both innovation and scientific rigor. These achievements align well with the criteria for a “Best Researcher Award.”

Education 🎓

Zhuang Jing holds a master’s degree in nursing, equipping her with advanced knowledge and skills to excel in clinical and research settings. Her academic background has provided a solid foundation for her pursuits in oncology and digestive cancer research.

Experience 💼

As the head nurse at Huzhou Central Hospital, Zhuang Jing has extensive experience in patient care, research coordination, and multidisciplinary collaboration. She is a key member of international research initiatives, particularly in colorectal cancer studies, where she integrates traditional Chinese and modern medical practices.

Research Interests On Oncology🔬

Her primary research interests lie in digestive tumors and intestinal microecology. Zhuang focuses on exploring the relationship between gut health and cancer, aiming to develop innovative therapeutic strategies for colorectal cancer.

Awards 🏆

Zhuang Jing’s contributions to oncology and nursing have earned her recognition in the medical community. She is currently nominated for the Best Researcher Award at the Forensic Scientist Awards, acknowledging her outstanding achievements in digestive cancer research.

Publications 📚

  1. Gut microbial subtypes and clinicopathological value for colorectal cancer

    • Authors: Shuwen Han, Jing Zhuang, Yifei Song, Xinyue Wu, Xiaojian Yu, Ye Tao, Jian Chu, Zhanbo Qu, Yinhang Wu, Shugao Han et al.

    • Year: 2024

  2. Trace elements in pancreatic cancer

    • Authors: Yao Yanjun, Zhuang Jing, Song Yifei, Gu Gangzhao, Yan Chenxin, Wei Qiang, Yan Qiang, Han Shuwen

    • Year: 2024

  3. Transcriptional profile and immune infiltration in colorectal cancer reveal the significance of inducible T‐cell costimulator as a crucial immune checkpoint molecule

    • Authors: Jian Chu, Yinghang Wu, Zhanbo Qu, Jing Zhuang, Jiang Liu, Shugao Han, Wei Wu, Shuwen Han

    • Year: 2024

  4. Aging characteristics of colorectal cancer based on gut microbiota

    • Authors: Yinhang Wu, Jing Zhuang, Qi Zhang, Xingming Zhao, Gong Chen, Shugao Han, Boyang Hu, Wei Wu, Shuwen Han

    • Year: 2023

  5. Developing a Diagnostic Model to Predict the Risk of Asthma Based on Ten Macrophage‐Related Gene Signatures

    • Authors: Xiaoshun Ai, Hong Shen, Yangyanqiu Wang, Jing Zhuang, Yani Zhou, Furong Niu, Qing Zhou, Si Qin

    • Year: 2022

  6. Screening of T Cell-Related Long Noncoding RNA-MicroRNA-mRNA Regulatory Networks in Non-Small-Cell Lung Cancer

    • Authors: Jing Zhuang

    • Year: 2020

  7. Analysis of T lymphocyte-related biomarkers in pancreatic cancer

    • Authors: Jing Zhuang

    • Year: 2020

  8. Progress in Research on Colorectal Cancer-Related Microorganisms and Metabolites

    • Authors: Jing Zhuang

    • Year: 2020

  9. Molecular characteristics associated with ferroptosis in hepatocellular carcinoma progression

    • Authors: Jing Zhuang

    • Year: 2020

  10. Biological roles of piRNAs in colorectal cancer

  • Authors: Jing Zhuang

  • Year: 2020

  1. Predicting biomarkers from classifier for liver metastasis of colorectal adenocarcinomas using machine learning models

  • Authors: Jing Zhuang

  • Year: 2020

  1. Biological significance of piRNA in liver cancer: a review

  • Authors: Jing Zhuang

  • Year: 2020

Conclusion 🔖

Zhuang Jing’s commitment to advancing colorectal cancer research through the lens of intestinal microecology has made her a prominent figure in the field. Her extensive publication record, clinical expertise, and dedication to improving patient outcomes exemplify her remarkable contributions to healthcare and medical research.

Zhijian Huang | Oncology | Excellence in Research

Dr. Zhijian Huang | Oncology | Excellence in Research

Fujian Cancer Hospital | China

Dr. Zhijian Huang is a distinguished Deputy Chief Physician at the Department of Breast Surgical Oncology at Fujian Medical University Cancer Hospital in Fuzhou, China. With extensive expertise in breast cancer treatment and reconstructive surgery, Dr. Huang has contributed significantly to understanding tumor metastasis mechanisms and immunological factors in breast cancer. He is currently expanding his research at Harvard University Beth Israel Deaconess Medical Center, focusing on molecular pathways and predictive models.

Professional profile👤

Google Scholar

Strengths for the Awards✨

  • Extensive Research Contributions: Dr. Huang has an impressive publication record, with 14 peer-reviewed articles, many in high-impact journals such as Frontiers in Oncology, BMC Cancer, and Biosafety and Health. His research spans crucial areas of breast cancer, including tumor metastasis mechanisms, immune microenvironments, and biomarker discovery.
  • Interdisciplinary Expertise: His skills in bioinformatics, molecular biology techniques (e.g., CRISPR/Cas9 gene editing), and clinical integration set him apart as a versatile researcher capable of bridging computational and experimental oncology.
  • Clinical Impact: Dr. Huang has contributed directly to patient care through advancements in comprehensive breast cancer treatment, breast reconstruction techniques, and real-world studies of therapeutic efficacy.
  • Recognition and Leadership: The two prestigious awards he received in 2023 for his work on artificial intelligence in breast cancer diagnostics and immune microenvironments reflect the impact and recognition of his research in the medical community.
  • International Collaboration: His postdoctoral research at Harvard University’s Beth Israel Deaconess Medical Center adds a global dimension to his work and highlights his active engagement in cutting-edge breast cancer research.

Education 🎓

Dr. Huang earned his Doctor of Medicine (M.D.) in Clinical Medicine from Southern Medical University in Guangzhou, China, in 2022. Prior to that, he completed his Master of Medicine at Fujian Medical University in 2009 and his Bachelor of Medicine at the same institution in 2005.

Experience 💼

Dr. Huang has been serving at Fujian Medical University Cancer Hospital since 2009, performing breast tumor surgeries, comprehensive treatments, and breast reconstructions. From 2016 to 2017, he trained at the Affiliated Cancer Hospital of Xiangya Medical College, focusing on advanced tumor plastic surgery techniques. In 2024, he joined Harvard University Beth Israel Deaconess Medical Center as a Postdoctoral Researcher, delving deeper into breast cancer mechanisms and therapeutic advancements.

Research Interests On Oncology🔬

His research revolves around tumor metastasis mechanisms, breast cancer immunology, and molecular biology techniques. He is skilled in Western blotting, lentiviral packaging, CRISPR/Cas9 gene editing, and developing mouse models. Dr. Huang also specializes in bioinformatics analysis, employing tools like SPSS and GraphPad Prism.

Awards 🏆

  • 2023: Third Prize, Fujian Medical Science and Technology Award for research on ultrasound-assisted artificial intelligence diagnosis of breast cancer, immune microenvironment, and metastatic molecular mechanisms.
  • 2023: Third Prize, Fujian Anti-Cancer Association Science and Technology Award for research on immune microenvironment, metastatic molecular mechanisms of breast cancer, and infusion port clinical applications.

Publications 📚

  • Title: Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer
    Authors: C Xiao, L Yang, L Jin, W Lin, F Zhang, S Huang, Z Huang
    Year: 2022
    Citations: 42

  • Title: Application of oncolytic virus in tumor therapy
    Authors: Z Huang, H Guo, L Lin, S Li, Y Yang, Y Han, W Huang, J Yang
    Year: 2023
    Citations: 29

  • Title: A novel XGBoost method to infer the primary lesion of 20 solid tumor types from gene expression data
    Authors: S Chen, W Zhou, J Tu, J Li, B Wang, X Mo, G Tian, K Lv, Z Huang
    Year: 2021
    Citations: 14

  • Title: miRNA-1260b promotes breast cancer cell migration and invasion by downregulating CCDC134
    Authors: Z Huang, S Zhen, L Jin, J Chen, Y Han, W Lei, F Zhang
    Year: 2023
    Citations: 12

  • Title: A novel framework to predict breast cancer prognosis using immune-associated LncRNAs
    Authors: Z Huang, C Xiao, F Zhang, Z Zhou, L Yu, C Ye, W Huang, N Li
    Year: 2021
    Citations: 12

  • Title: HAUS5 is a potential prognostic biomarker with functional significance in breast cancer
    Authors: Z Huang, J Yang, W Qiu, J Huang, Z Chen, Y Han, C Ye
    Year: 2022
    Citations: 10

  • Title: 肝癌病人术后早期肠内与肠外营养支持治疗的比较
    Authors: 周东, 刘胜, 应敏刚, 黄峰, 吴贤毅, 黄志坚
    Year: 2012
    Citations: 10

  • Title: Comprehensive analysis of immune ferroptosis gene in renal clear cell carcinoma: Prognosis and influence of tumor microenvironment
    Authors: LH Yang, LZ Xu, ZJ Huang, HH Pan, M Wu, QY Wu, T Lu, YP Zhang
    Year: 2022
    Citations: 5

  • Title: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer
    Authors: W Huang, C Wang, Y Shen, Q Chen, Z Huang, J Liu, X Lin, L Wang, F Wu
    Year: 2024
    Citations: 4

  • Title: Systematic pan-cancer analysis identifies cGAS as an immunological and prognostic biomarker
    Authors: P Chen, X Yang, P Wang, H He, Y Chen, L Yu, H Fang, F Wang, Z Huang
    Year: 2023
    Citations: 4

Conclusion 🔖

Dr. Zhijian Huang’s illustrious career is marked by a deep commitment to advancing breast cancer treatment through surgical expertise and cutting-edge research. His work continues to shape the future of cancer therapy, bridging molecular insights with clinical applications to improve patient outcomes worldwide.